Leader in Downstream, High-Volume
Life Science Applications

Highly resilient long-term growth profile

Embedded in small molecule, biologics and novel modality testing applications

Industry-leading profitability

31.0%

Adj. Operating Margin

2024

Strong free cash flow generation

23%

Avg FCF as % of Sales

2020-24

Latest News

Latest Events

Our Portfolio

Featured Investor Presentation